Sequencing Reagents Market Analysis

  • Report ID: 5883
  • Published Date: Sep 16, 2025
  • Report Format: PDF, PPT

Sequencing Reagents Market Segmentation:

Technology Segment Analysis  

The next-generation sequencing segment in the will grow the most by the forecast period and will hold almost 45% in the sequencing reagents market because of its high possibility for the growth of companion diagnostics and customized medicine for the treatment of chronic diseases. Next-generation sequencing (NGS) may empower more centered and profoundly personalized cancer treatment, with the National Comprehensive Cancer Arrange and European Society for Restorative Oncology rules presently prescribing NGS for everyday clinical hone for a few tumor sorts. Be that as it may, NGS usage, and thus persistent get to, changes over Europe; a multi-stakeholder collaboration is required to set up the conditions required to progress this disparity. In that respect, the analysts set up European Collusion for Customized Pharmaceutical (EAPM)-led master boards amid the primary half of 2021, counting key partners from over 10 European countries covering restorative, financial, quiet, industry, and legislative mastery. NGS tests are ordinarily run to realize a foreordained scope, which is the normal profundity of sequencing overall focused on genome positions. Scope at any genome arrangement can be calculated, after mapping sequencing peruses to the reference genome, by tallying the number of autonomous peruses that cover that position and thus will propel the sequencing reagents market.

Application Segment Analysis  

The oncology segment is expected to hold around 38% share of the global sequencing reagents market by 2035, owing to the increasing implementation of next-generation sequencing for cancer diagnosis and treatment across the world. Next-generation sequencing testing selection rates have expanded in later a long time, with rates for progressed non–small cell lung cancer (aNSCLC), metastatic colorectal cancer (mCRC), metastatic breast cancer (mBC), and progressed melanoma expanding from less than 1% in 2011 to approximately 40% in 2022. Thus, it will help this segment to have the largest growth in the sequencing reagents market.

Our in-depth analysis of the global sequencing reagents market includes the following segments:

     Type

  • Template Kits
  • Library Kits
  • Control Kits
  • Sequencing Kits

     Technology

  • Next Generation Sequencing
  • Sanger Sequencing
  • Third Generation Sequencing

     Application

  • Clinical Investigation
  • Oncology
  • Forensics & Agrigenomics
  • Virology
  • RNA Sequencing
  • Metagenomics

     Reagent Type

  • DNTP Reagent
  • DNA Polymerase Reagent
  • Ampicillin Reagent
  • Buffer Solution Reagent
  • NGS Reagent
  • Serum Reagent Kits

     End-Use Industry

  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of sequencing reagents is assessed at USD 10.62 billion.

The global sequencing reagents market size was valued at over USD 9.73 billion in 2025 and is expected to expand at a CAGR of over 10.2%, surpassing USD 25.7 billion revenue by 2035.

North America sequencing reagents market achieves a 34% share by 2035, fueled by the region’s advanced healthcare system and leadership in medical innovations.

Key players in the market include Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN, BGI, Pacific Biosciences of California, Inc., F. Hoffmann-La Roche A.G., Oxford Nanopore Technologies, Agilent Technologies, Inc., Fluidigm Corporation, ArcherDX, Inc., Myriad Genetics. Inc., Eurofins Scientific, Takara Bio Inc., Mitsui Information Co., Ltd.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos